CIK 0001528115 · Non-accelerated filer<br>Smaller reporting company
Annexon, Inc.
Sign in to watch- Ticker
- ANNX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 275414423
- Phone
- (650) 822-5500
- Business address
- 1400 SIERRA POINT PARKWAY, BLDG C, SUITE 200, BRISBANE, CA, 94005
- Open-market buys, last 90 days
- $99,829
- in 1 filing
- Open-market sales, last 90 days
- $0
- in 0 filings
Net +$99,829. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-02-16 | Overdorf Michael EVP & CHIEF BUSINESS OFFICER | Grant or award · Stock Option (Right to Buy) | +160,000 | 160,000 | ||
| 2024-02-16 | Lew Jennifer EVP & CHIEF FINANCIAL OFFICER | Grant or award | +39,000 | 84,651 | ||
| 2024-02-16 | Lew Jennifer EVP & CHIEF FINANCIAL OFFICER | Grant or award · Stock Option (Right to Buy) | +160,000 | 160,000 | ||
| 2024-02-12 | Overdorf Michael EVP & CHIEF BUSINESS OFFICER | Sale | −1,349 | $5.53 | $7K | 48,592 |
| 2024-02-12 | Love Douglas PRESIDENT AND CEO | Sale | −5,782 | $5.54 | $32K | 196,121 |
| 2024-02-12 | Lew Jennifer EVP & CHIEF FINANCIAL OFFICER | Sale | −1,809 | $5.54 | $10K | 45,651 |
| 2024-02-12 | Yednock Ted EVP & CHIEF INNOVATION OFFICER | Sale | −1,810 | $5.54 | $10K | 36,075 |
| 2023-12-27 | Yednock Ted EVP & Chief Innovation Officer | Option exercise 10b5-1 | +10,615 | $1.41 | $15K | 48,500 |
| 2023-12-27 | Yednock Ted EVP & Chief Innovation Officer | Option exercise 10b5-1 | +10,385 | $1.85 | $19K | 58,885 |
| 2023-12-27 | Yednock Ted EVP & Chief Innovation Officer | Sale 10b5-1 | −21,000 | $4.52 | $95K | 37,885 |
| 2023-12-27 | Yednock Ted EVP & Chief Innovation Officer | Option exercise 10b5-1 | +10,615 | $1.41 | $15K | 10,615 |
| 2023-12-27 | Yednock Ted EVP & Chief Innovation Officer | Option exercise 10b5-1 | +10,385 | $1.85 | $19K | 21,000 |
| 2023-12-27 | Yednock Ted EVP & Chief Innovation Officer | Sale 10b5-1 | −21,000 | $4.52 | $95K | 0 |
| 2023-12-27 | Yednock Ted EVP & Chief Innovation Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −10,615 | 0 | ||
| 2023-12-27 | Yednock Ted EVP & Chief Innovation Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −10,385 | 36,000 | ||
| 2023-12-26 | Satter Muneer A Director | Purchase | +350,000 | $2.88 | $1.0M | 7,406,024 |
| 2023-08-01 | Dananberg Jamie Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +275,000 | 275,000 | ||
| 2023-07-11 | Yednock Ted EVP & Chief Innovation Officer | Sale 10b5-1 | −1,057 | $3.84 | $4K | 37,885 |
| 2023-07-11 | Overdorf Michael EVP & Chief Business Officer | Sale | −978 | $3.84 | $4K | 45,802 |
| 2023-07-11 | Lew Jennifer EVP & Chief Financial Officer | Sale | −1,057 | $3.84 | $4K | 47,460 |
Page 7 of 15 · 292 trades